<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Key opportunities include oncolytic viruses, CAR-T and bispecific antibodies, combination regimens, biomarker-led care, hematologic cancers, expanded solid-tumor indications, outcome-based reimbursement, and cost-efficient manufacturing in Asia-PacificDublin, Aug. 10, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/4845949/cancer-immunotherapy-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=b33rr3&amp;utm_campaign=2324005+-+Global+Cancer+Immunotherapy+Market+Report+2026+%7c+Industry+to+Reach+%24311.43+Billion+by+2031%2c+Driven+by+Precision+Oncology+and+Cell+Therapy+Innovation&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Cancer Immunotherapy - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Cancer Immunotherapy - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy market was valued at USD 144.80 billion in 2025 and is projected to increase from USD 164.51 billion in 2026 to USD 311.43 billion by 2031. The market is expected to register a compound annual growth rate of 13.62% during the 2026-2031 forecast period. Market expansion is being supported by the rising global incidence of solid tumours, ageing populations, lifestyle-related cancer risks, broader biomarker screening and increased adoption of precision oncology. Lung, colorectal and breast cancers continue to account for substantial treatment demand. Public cancer awareness initiatives, earlier diagnosis and expanding reimbursement for advanced therapies are also increasing the number of patients eligible for cancer immunotherapy. Long-Term Survival Benefits Strengthen Clinical Adoption Evidence of improved long-term survival compared with chemotherapy continues to influence oncology treatment protocols. Five-year follow-up data from CheckMate 9LA showed that nivolumab plus ipilimumab and chemotherapy achieved an overall survival rate of 18% in metastatic non-small cell lung cancer, compared with 11% for chemotherapy alone. Clinical guidelines increasingly prioritise immune checkpoint inhibitors in first-line settings for eligible patients, while real-world evidence is supporting wider inclusion in hospital formularies. Additional market growth is anticipated from expanding FDA and European Medicines Agency label approvals for PD-1 and PD-L1 inhibitors, alongside a rapidly advancing pipeline of CAR-T therapies, bispecific antibodies, cancer vaccines and oncolytic viruses. Combination regimens are also gaining strategic importance as companies seek to improve tumour-specific immune responses and address treatment resistance. High Treatment Costs Remain a Major Market Restraint Pricing and reimbursement pressures continue to affect commercial adoption. Several CAR-T therapies exceed USD 300,000 per treatment course, while Iovance Biotherapeutics' Amtagvi carries a list price of USD 515,000. These costs are accelerating the use of outcome-based reimbursement agreements, particularly in the United States. Tiered pricing, reimbursement caps and compulsory-licensing risks in emerging markets are also encouraging manufacturers to improve production efficiency and reduce advanced therapy manufacturing costs. Immune-related adverse events requiring intensive clinical management represent another significant restraint. Providers must balance efficacy with patient selection, monitoring requirements and the operational resources needed to manage complex treatment protocols. Cancer Immunotherapy Market Segment Insights Monoclonal antibodies generated 66.88% of market revenue in 2025, maintaining the largest share among therapy types. Continued first-line use in lung cancer, melanoma and renal cancer is expected to support segment growth, with the monoclonal antibody market projected to reach USD 192.36 billion by 2031. Oncolytic virus therapies are forecast to record the fastest therapy-type growth, advancing at a CAGR of 23.28%. Late-stage clinical assets, manufacturing partnerships and investment in viral platforms are improving the segment's commercial potential. Strategic activity includes Pfizer's investment in Ignite Immunotherapy and Bristol Myers Squibb's alliance with BioNTech on bispecific antibody programmes. Lung cancer represented 25.12% of global sales in 2025, making it the leading cancer indication. Its position is supported by new adjuvant approvals, screening programmes and earlier diagnosis. Hematologic malignancies are projected to grow at the fastest CAGR of 21.42%, reaching USD 81.73 billion by 2031. CAR-T approvals for multiple myeloma and acute lymphoblastic leukaemia, together with bispecific antibodies for patients who are not candidates for cell therapy, are broadening the addressable market. Regional Cancer Immunotherapy Market Outlook North America accounted for 48.10% of global revenue in 2025. The region benefits from rapid FDA approvals, strong biotechnology investment, extensive clinical research infrastructure and growing use of outcome-based reimbursement. National Cancer Institute funding across 71 designated cancer centres supports translational research, investigator-led trials and combination therapy studies. Canada is also investing in specialised cell therapy centres and domestic manufacturing capacity. Asia-Pacific is projected to register the fastest regional CAGR of 17.74% through 2031. China leads regional activity with more than 400 CAR-T clinical programmes, expanding viral-vector capacity and accelerated regulatory review pathways. Japan remains an early adopter of cancer immunotherapies, while India is advancing lower-cost domestic CAR-T manufacturing to improve access and support export opportunities. Europe is expected to maintain steady growth through coordinated clinical-trial networks, precision biomarker research and established biomanufacturing clusters. Health technology assessment requirements across major European markets continue to place pressure on treatment prices, supporting greater adoption of performance-linked discounts and outcome-based agreements. Report Scope <ul><li>Therapy types: Monoclonal antibodies, cancer vaccines, immunomodulators, cell-based therapies, oncolytic virus therapies and combination regimens</li><li>Cancer types: Lung cancer, breast cancer, melanoma and skin cancers, prostate cancer, hematologic malignancies and other solid tumours</li><li>End users: Hospitals and clinics, academic and cancer research centres, and ambulatory and specialty infusion centres</li><li>Routes of administration: Intravenous, subcutaneous and intratumoral</li><li>Regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America</li></ul> Competitive Landscape Companies covered in the cancer immunotherapy market report include Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Roche, Pfizer, Novartis, GlaxoSmithKline, Eli Lilly and Company, AbbVie, Johnson &amp; Johnson, Regeneron Pharmaceuticals, Sanofi, BeiGene, Seagen, BioNTech, Moderna, Iovance Biotherapeutics, OSE Immunotherapeutics and Innovent Biologics. The report provides market forecasts in USD, detailed analysis of growth drivers and restraints, segment-level revenue projections, regional market assessments and competitive intelligence. Additional benefits include a market estimate sheet in Excel format and three months of analyst support. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/4845949/cancer-immunotherapy-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=b33rr3&amp;utm_campaign=2324005+-+Global+Cancer+Immunotherapy+Market+Report+2026+%7c+Industry+to+Reach+%24311.43+Billion+by+2031%2c+Driven+by+Precision+Oncology+and+Cell+Therapy+Innovation&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/dd8ubm</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MzkyOGY4MjYtYjY2Ny00MmM0LWJmMDAtNTAwNDQ0ZjAzM2IyLTEwMjY3MzctMjAyNi0wOC0xMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global Cancer Immunotherapy Market Report 2026 | Industry to Reach $311.43 Billion by 2031, Driven by Precision Oncology and Cell Therapy Innovation

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn